DelveInsight’s, “Aplastic Anemia - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Aplastic Anemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Aplastic Anemia: Overview
Aplastic anemia is a medical condition that damages stem cells in a person’s bone marrow. These cells are responsible for making red blood cells, white blood cells, and platelets, which are vital to human health. A rare and serious condition, aplastic anemia can develop at any age. It can occur suddenly, or it can come on slowly and worsen over time. It can be mild or severe. Treatment for aplastic anemia might include medications, blood transfusions or a stem cell transplant, also known as a bone marrow transplant. The most common cause of aplastic anemia is from your immune system attacking the stem cells in your bone marrow. Other factors that can injure bone marrow and affect blood cell production include: Radiation and chemotherapy treatments, exposure to toxic chemicals, use of certain drugs, autoimmune disorders, a viral infection and unknown factors.
The companies and academics are working to assess challenges and seek opportunities that could influence Aplastic Anemia R&D. The therapies under development are focused on novel approaches for Aplastic Anemia.
This segment of the Aplastic Anemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Aplastic Anemia Emerging Drugs
PF-06462700: Pfizer
PF-06462700 is classified as an immunosuppressant/ immunosuppressive agent. It is the purified, concentrated, and sterile gamma globulin, primarily monomeric immunoglobulin G (IgG), from hyperimmune serum of horses that are immunized with human thymus lymphocytes. PF-06462700 is being developed by Pfizer for Aplastic anaemia and is currently in phase III stage of development.
REGN7257: Regeneron Pharmaceuticals
REGN7257is being developed by Regeneron Pharmaceuticals for Aplastic Anemia. It is currently in phase I/II stage of development. LB-001 acts as a modulator of Interleukin 2 and immunomodular.
Further product details are provided in the report……..
This segment of the report provides insights about the different Aplastic Anemia drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 10+ key companies which are developing the Aplastic Anemia. The companies which have their Aplastic Anemia drug candidates in the most advanced stage, i.e. Phase III include, Pfizer.
DelveInsight’s report covers around 15+ products under different phases of clinical development like
Aplastic Anemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Aplastic Anemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Aplastic Anemia drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
Aplastic Anemia: Overview
Pipeline Therapeutics
Therapeutic Assessment
Aplastic Anemia– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Aplastic Anemia Collaboration Deals
Late Stage Products (Phase III)
PF-06462700: Pfizer
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Drug Name: Company Name
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Omidubicel: Gamida Cell
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Hu-PHEC: Hemogenyx
Drug profiles in the detailed report…..
Inactive Products
Aplastic Anemia Key Companies
Aplastic Anemia Key Products
Aplastic Anemia- Unmet Needs
Aplastic Anemia- Market Drivers and Barriers
Aplastic Anemia- Future Perspectives and Conclusion
Aplastic Anemia Analyst Views
Aplastic Anemia Key Companies
Appendix
List of Table
Table 1: Total Products for Aplastic Anemia
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Aplastic Anemia
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Pfizer
• Regeneron Pharmaceuticals
• Regen BioPharma
• Omidubicel
• Cellenkos
• Hemogenyx
